 NEW HAVEN, Conn., Aug. 07, 2020 GLOBE NEWSWIRE -- Arvinas, Inc. Nasdaq: ARVN, a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat at the 2020 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 11 at 10:20 a.m. ET. A live audio webcast of the presentation will be available here and on the Companys website at A replay of the webcast will be archived on the Arvinas website for 30 days following the presentation.About Arvinas Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the bodys own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ERHER2- breast cancer. For more information, visit for Arvinas Investors Will OConnor, Stern Investor Relations Kirsten Owens, Arvinas Communications 